Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer
نویسندگان
چکیده
Background: Lazertinib is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to overcome EGFR T790M mutation. Currently, lazertinib approved for usage in the acquired mutation population based on promising clinical and safety profiles. In this study, we evaluated outcomes of mutated non-small cell lung cancer (NSCLC) patients real-world setting.
منابع مشابه
Acquired T790M resistance do afatinib in EGFR mutated lung adenocarcinoma.
The patient was a 73-year-old female who had neversmoked and who had received a diagnosis of stage IVlung adenocarcinoma. In direct sequence method, the resected tumor specimen revealed Ex19 E746_A750del (deletion IN frame) 2235_2249del15 (Deletion). But T790M mutation was not detected in the specimen. This patient, not previouslytreated with gefitinib or erlotinib,had afatinib at a 40-mg dose....
متن کاملManaging acquired resistance in EGFR-mutated non-small cell lung cancer.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) deliver high response rates with relatively modest toxicity in patients with advanced EGFR-mutated non-small cell lung cancer. Despite this, nearly all tumors eventually develop resistance to first-line therapy. At present, the only standard treatment option for patients with acquired resistance is cytotoxic chemotherapy....
متن کاملAcquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291. We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a ce...
متن کاملFatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Metabolic reprogramming is widely known as a hallmark of cancer cells to allow adaptation of cells to sustain survival signals. In this report, we describe a novel oncogenic signaling pathway exclusively acting in mutated epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) with acquired tyrosine kinase inhibitor (TKI) resistance. Mutated EGFR mediates TKI resistance throu...
متن کاملNoninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
PURPOSE Tumors from 50% of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer patients that develop resistance to gefitinib or erlotinib will contain a secondary EGFR T790M mutation. As most patients do not undergo repeated tumor biopsies we evaluated whether EGFR T790M could be detected using plasma DNA. EXPERIMENTAL DESIGN DNA from plasma of 54 patients with known cli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational lung cancer research
سال: 2023
ISSN: ['2226-4477', '2218-6751']
DOI: https://doi.org/10.21037/tlcr-23-160